Evaluation of the therapeutic effect and introduction to the scope of application of mirikizumab

Mirikizumab (Mirikizumab) is a monoclonal antibody targeting interleukin-23 (IL-23), developed by Eli Lilly (Eli Developed by Lilly () company, it is mainly used to treat moderately to severe active ulcerative colitis (UC) and other chronic inflammatory diseases. The drug selectively inhibits IL-23 p19 subunit and blocks pro-inflammatory signaling pathways, thereby effectively regulating abnormal responses of the immune system. It is an important new breakthrough in the field of inflammatory bowel disease treatment in recent years.

In terms of therapeutic effect, militizumab has shown significant efficacy in multiple phase III clinical studies. Studies have shown that a higher proportion of patients using militizumab achieved clinical remission, mucosal healing and symptom improvement after the 12-week induction treatment period; and during the maintenance treatment stage, patients who continued to use it could maintain long-term remission. Compared with traditional immunosuppressants, it has a faster onset of action and longer maintenance of remission. At the same time, the safety data is also relatively good. Common side effects include upper respiratory tract infection, headache and injection site reaction, etc., which are usually mild.

At present, militizumab has been approved in the EU, the United States and other places for the treatment of moderate to severe ulcerative colitis. It is mainly suitable for patients who are ineffective or intolerant to traditional treatments (such as glucocorticoids, azathioprine) or TNF-α inhibitors (such as infliximab). In addition, militizumab is also undergoing clinical trials for autoimmune diseases such as Crohn's disease and psoriasis, and is expected to expand its indications to a wider range of inflammatory diseases.

Overall, militizumab is a new biological agent with a clear target, stable efficacy, and relatively low side effects. It provides a new treatment option for patients with chronic inflammatory diseases such as moderate to severe ulcerative colitis. With successive approvals in major markets around the world, its accessibility will gradually increase. Militizumab is expected to become a more effective and safer treatment alternative for patients who have long been troubled by inflammatory bowel disease and for whom traditional treatments are ineffective.

Reference materials:https://www.drugs.com/